Research laboratory suppliers consider clinical targets in M&A (Mergers and Acquisitions) activities
This article was originally published in Clinica
The drive to extend product lines and exploit life science technologies were key reasons for the high level of M&A activity among medical device and diagnostics companies in the second half of the 1990s. Manufacturers' pursuit of diversification, and other industry twists and turns, are discussed in the 2000 edition of Mergers and Acquisitions in the Laboratory Equipment and Analytical Instrument Industries, from PJB Publications' Infocom reports, reviewed here by author Dr Gordon Wilkinson.
You may also be interested in...
All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.